Medi-Cal prior authorization would start in May for six companies refusing to pay added rebates.
MEDI-CAL FORMULARY REVIEW FOR PRIOR AUTHORIZATION RESTRICTIONS is to be completed no later than early May, Medi-Cal said. The state Medicaid agency is reviewing its formulary for products from six companies that have refused to pay manufacturer rebates. When Medi-Cal instituted a 10% supplemental manufacturer rebate program in July as a cost-saving measure, six companies refused to pay the rebate: DuPont Merck, Hoechst-Roussel, Pfizer, Sandoz, SmithKline Beecham, and Wyeth-Ayerst.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth